Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with aids

New England Journal of Medicine

Volumn 333, Issue 10, 1995, Pages 615-620

  Drew, W Lawrence ^a   Ives, David ^a   Lalezari, Jacob P ^a   Crumpacker, Clyde ^a   Follansbee, Stephen E ^a   Spector, Stephen A ^a   Benson, Constance A ^a   Friedberg, Dorothy N ^a   Hubbard, Larry ^a   Stempien, Mary Jean ^a   Shadman, Anna ^a   Buhles, William ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANEMIA; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INFECTION RISK; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINITIS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADMINISTRATION, ORAL; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; CYTOMEGALOVIRUS RETINITIS; DISEASE PROGRESSION; FEMALE; GANCICLOVIR; HUMANS; INJECTIONS, INTRAVENOUS; MALE; SURVIVAL ANALYSIS;

EID: 0029143294     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199509073331002     Document Type: Article

References (23)

1. Holland GN, Pepose JS, Pettit TH, Gottlieb MS, Yee RD, Foos RY Acquired immune deficiency syndrome: ocular manifestations. Ophthalmology 1983; 90: 859-873
2. Pepose JS, Holland GN, Nestor MS, Cochran AJ, Foos RY Acquired immune deficiency syndrome: pathogenic mechanisms of ocular disease. Ophthalmology 1985; 92: 472-484
3. Palestine AG, Rodrigues MM, Macher AM, Ophthalmic involvement in acquired immunodeficiency syndrome. Ophthalmology 1984; 91: 1092-1099
4. Jabs DA, Green WR, Fox R, Polk BF, Bartlett JG Ocular manifestations of acquired immune deficiency syndrome. Ophthalmology 1989; 96: 1092-1099
5. Jabs DA, Enger C, Bartlett JG Cytomegalovirus retinitis and acquired immunodeficiency syndrome. Arch Ophthalmol 1989; 107: 75-80
6. Drew WL Cytomegalovirus infection in patients with AIDS. J Infect Dis 1988; 158: 449-456
7. Holland GN, Sidikaro Y, Kreiger AE, Treatment of cytomegalovirus retinopathy with ganciclovir. Ophthalmology 1987; 94: 815-823
8. Jabs DA, Newman C, De Bustros S, Polk BF Treatment of cytomegalovirus retinitis with ganciclovir. Ophthalmology 1987; 94: 824-830
9. Orellana J, Teich SA, Friedman AH, Lerebours F, Winterkorn J, Mildvan D Combined short- and long-term therapy for the treatment of cytomegalovirus retinitis using ganciclovir (BW B759U). Ophthalmology 1987; 94: 831-838
10. Jacobson MA, O'Donnell JJ, Brodie HR, Wofsy C, Mills J Randomized prospective trial of ganciclovir maintenance therapy for cytomegalovirus retinitis. J Med Virol 1988; 25: 339-349
11. Jacobson MA, Causey D, Polsky B, A dose-ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus retinitis in AIDS. J Infect Dis 1993; 168: 444-448
12. Jacobson MA, O'Donnell JJ, Mills J Foscarnet treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome. Antimicrob Agents Chemother 1989; 33: 736-741
13. Lehoang P, Girard B, Robinet M, Foscarnet in the treatment of cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology 1989; 96: 865-874
14. Walmsley SL, Chew E, Read SE, Treatment of cytomegalovirus retinitis with trisodium phosphonoformate hexahydrate (foscarnet). J Infect Dis 1988; 157: 569-572
15. Anderson RD, Griffy KG, Jung D, Dorr A, Hulse JD, Smith RB Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients. Clin Ther 1995; 17: 425-432
16. Spector SA, Busch DF, Follansbee S, Pharmacokinetic, safety and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. J Infect Dis 1995; 171: 1431-1437
17. Plotkin SA, Drew WL, Felsenstein D, Hirsch MS Sensitivity of clinical isolates of human cytomegalovirus to 9-(1,3-dihydroxy-2-propoxymethyl)guanine. J Infect Dis 1985; 152: 833-834
18. Drew WL, Miner R, Saleh E Antiviral susceptibility testing of cytomegalovirus: criteria for detecting resistance to antivirals. Clin Diagn Virol 1993; 1: 179-185
19. Drew WL, Miner RC, Busch DF, Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis 1991; 163: 716-719
20. Studies of Ocular Complications of AIDS Research Group, AIDS Clinical Trials Group. Foscarnet-ganciclovir cytomegalovirus retinitis trial. 4. Visual outcomes. Ophthalmology 1994; 101: 1250-1261
21. Studies of Ocular Complications of AIDS Research Group, in Collaboration with the AIDS Clinical Trials Group. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med 1992; 326: 213-220
22. Martin DF, Parks DJ, Mellow SD, Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant: a randomized controlled clinical trial. Arch Ophthalmol 1994; 112: 1531-1539
23. Fletcher CV, Balfour HH Jr Evaluation of ganciclovir for cytomegalovirus disease. DICP 1989; 23: 5-12